Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
16 Noviembre 2023 - 6:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission
is to develop medicines that meaningfully improve and extend the
lives of patients facing deadly diseases, today announced the
appointment of Thomas Riga as Chief Operating and Commercial
Officer.
“We are excited to welcome Tom to the Chimerix team as his
leadership and extensive market knowledge will be a great asset as
we advance ONC201 toward commercialization,” said Mike Andriole,
Chief Executive Officer of Chimerix. “Tom’s in-depth oncology
experience in commercial launch readiness, brand marketing, market
access, and reimbursement will accelerate our readiness efforts
with ONC201. Additionally, his broader operational and business
development experience will enhance our ambitious plans for
Chimerix’s growth.”
“The exciting work Chimerix is advancing in support of brain
cancer patients who have so few treatment options is inspirational
and I feel privileged to be joining this team,” said Mr. Riga.
“Given the poor prognosis for patients with H3 K27M-mutant glioma,
our goal is to bring this potentially life-altering drug to
patients as quickly as possible.”
Prior to joining Chimerix, Mr. Riga served as President and
Chief Executive Officer at Spectrum Pharmaceuticals, through its
acquisition in July. Prior to being named CEO of Spectrum, Mr. Riga
served as the Chief Commercial Officer for nine years and Chief
Operating Officer for five years. Before joining Spectrum, he led
multiple oncology product teams holding commercial sales and
marketing leadership positions at Dendreon, Amgen and Eli Lilly and
Company. He began his career at Wyeth Ayerst Laboratories in
pharmaceutical manufacturing. Mr. Riga holds a B.S. in Biology and
Chemistry from St. Lawrence University.
About Chimerix Chimerix is a biopharmaceutical
company with a mission to develop medicines that meaningfully
improve and extend the lives of patients facing deadly diseases.
The Company’s most advanced clinical-stage development program,
ONC201, is in development for H3 K27M-mutant glioma.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that are subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. Forward-looking statements
include those relating to, among other things, the advancement of
ONC201 towards commercialization and our plans for Chimerix’s
growth. Among the factors and risks that could cause actual results
to differ materially from those indicated in the forward-looking
statements are risks related to the timing, completion and outcome
of the Phase 3 ACTION study of ONC201; risks associated with
repeating positive results obtained in prior preclinical or
clinical studies in future studies; risks related to the clinical
development of ONC206; and additional risks set forth in the
Company's filings with the Securities and Exchange Commission.
These forward-looking statements represent the Company's judgment
as of the date of this release. The Company disclaims, however, any
intent or obligation to update these forward-looking
statements.
Inducement Grant
In connection with the hiring of Mr. Riga, on November 16, 2023,
the Compensation Committee of Chimerix’s Board of Directors granted
Mr. Riga a non-qualified stock option to purchase 800,000 shares of
Chimerix’s common stock, with an exercise price per share equal to
the closing price of Chimerix’s common stock on the grant date. The
stock option has a 10-year term and will vest over four years, with
one-fourth vesting on the one-year anniversary of the grant date
and the remaining three-fourths vesting over the following three
years in equal monthly installments. The stock option is subject to
the terms of Chimerix’s 2013 Equity Incentive Plan but was granted
outside of the 2013 Equity Incentive Plan, and was granted as an
inducement material to Mr. Riga entering into employment with
Chimerix in accordance with Nasdaq Listing Rule 5635(c)(4).
CONTACTS:
Michelle LaSpaluto919 972-7115ir@chimerix.com
Will O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Chimerix (NASDAQ:CMRX)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024